- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05234723
Ganciclovir Resistant Cytomegalovirus Infection in SOT Recipients.
Epidemiological Burden of and Risk Factors for Ganciclovir Resistant Cytomegalovirus in Solid Organ Transplant Patients: Multicentre Cohort Study
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Cytomegalovirus (CMV) is an important cause of morbidity and mortality in solid organ transplant (SOT) patients. Ganciclovir is the first line therapy for treatment and prevention of CMV infection in SOT recipients, with established efficacy and relatively safe profile.
Ganciclovir-resistant (GCV-R) CMV is an uncommon but frightening clinical problem due to limited, toxic and less effective therapeutic alternative drugs. Indeed, some studies indicate that GCV-R is associated with significant additional attributable morbidity and mortality in SOT recipients compared with ganciclovir susceptible (GCV-S) CMV disease.
Few data are available about the incidence of GCV-R-CMV in SOT patients showing a range from 0% to 3% . The serological mismatch group and the type of SOT have been reported as the main factors influencing such range. Indeed, in one of the largest experience now available, the incidence of GCV-R accounted up to 12% in a cohort of lung transplant recipients.Risk factors for ganciclovir resistance development appear to be the high-risk D+/R- subset, high viral loads, increased durations of antiviral drug exposure and the use of more potent immunosuppression. However, these reports come from small, monocentric experiences with a limited number of cases.
In general, mutations that confer resistance to ganciclovir are not present at baseline but emerge and become amplified over time, especially in the presence of an incompletely suppressive drug exposure. The GCV-R is due to mutations in UL97 and UL54 genes. UL97 mutations confer various degrees of phenotypic resistance to ganciclovir. Mutations in UL54 determine higher-level resistance to ganciclovir and usually appear as a second step after mutations in UL97.
Second-line strategies for the treatment of GCV-R CMV are based on high dose of GCV administration or foscarnet/cidofovir use, both with a high risk of metabolic and renal dysfunction. Alternative strategies are based on the use of adjunctive treatments such as cytomegalovirus immunoglobulins (IVIG), infusions of CMV-specific Tcells or several drugs with indirect anti-CMV action (mTOR inhibitors sirolimus and everolimus, leflunomide and artesunate). Finally, the new antiviral drugs approved for prophylaxis (letermovir) or in advanced clinical development (maribavir, brincidofovir), are reported as anecdotical alternative strategies for the treatment of GCV-R CVM infection. The limited therapeutic strategies for GCV-R CMV treatment highlight the need for new strategies to prevent resistance development.
The investigators carry-out a multicenter retrospective observational study to define incidence of GCV-R CMV-infection in SOT patients and to identify the risk factors for its development in SOT recipients. Data from this study could be useful to design further studies aimed at preventing and improving the patient management of GCV-R CMV infections.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Renato Pascale, MD
- Telefonnummer: +390512143199
- E-Mail: renato.pascale@aosp.bo.it
Studieren Sie die Kontaktsicherung
- Name: Maddalena Giannella, MD, PHD
- Telefonnummer: +390512143199
- E-Mail: maddalena.giannella@unibo.it
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
All adult (≥ 18 years) patients who underwent SOT developing CMV-infection during the study period will be screened for inclusion according to inclusion and exclusion criteria. Eligible patients will be classified as cases or controls according to the following definitions:
- Case: SOT recipients with genotypically confirmed GCV-R CMV-event;
- Control: SOT recipients with "presumed" GCV-S CMV-event on the basis of good microbiological and clinical response to standard GCV/VGC treatment.
Beschreibung
Inclusion Criteria:
- Diagnosis of CMV infection in adult (age ≥ 18 years) patients underwent SOT
- Ability to understand the purpose of the study and provide signed and dated informed consent
Exclusion Criteria:
- Lack of clinical and/or laboratory data to establish the type of CMV event
- Lack of the serological mismatch at transplantation
- Lack of the type of SOT
- Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
To define incidence of GCV-R CMV-infection in SOT patients
Zeitfenster: Through study completion, an average of 1 year
|
To define incidence of GCV-R CMV-infection in SOT patients
|
Through study completion, an average of 1 year
|
To define the risk factors for GCV-R CMV-infection development in SOT patients
Zeitfenster: Through study completion, an average of 1 year
|
To define the risk factors for GCV-R CMV-infection development in SOT patients
|
Through study completion, an average of 1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
To compare type of CMV episode between SOT patients with GCV-R versus GCV-S CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To compare type of CMV episode: infection or disease (the last cathegorized as CMV syndrome or Tissue invasion) between SOT patients with GCV-R versus GCV-S CMV-infection.
|
Through study completion, an average of 1 year
|
To compare virological cure between SOT patients with GCV-R versus GCV-S CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To compare virological cure at 30, 60 and 90 days after CMV infection diagnosis and relapse of CMV infection between SOT patients with GCV-R versus GCV-S CMV-infection.
|
Through study completion, an average of 1 year
|
To compare clinical cure between SOT patients with GCV-R versus GCV-S CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To compare clinical cure at 30, 60 and 90 days after CMV infection diagnosis between SOT patients with GCV-R versus GCV-S CMV-infection.
|
Through study completion, an average of 1 year
|
To compare graft outcome between SOT patients with GCV-R versus GCV-S CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To compare graft failure rate and the need of re-SOT between SOT patients with GCV-R versus GCV-S CMV-infection between SOT patients with GCV-R versus GCV-S CMV-infection.
|
Through study completion, an average of 1 year
|
To compare the need of ICU and hospital stay between SOT patients with GCV-R versus GCV-S CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To compare total length of ICU and hospital stay between SOT patients with GCV-R versus GCV-S CMV-infection.
|
Through study completion, an average of 1 year
|
To compare the need of readmission in ICU and/or hospital between SOT patients with GCV-R versus GCV-S CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To compare the need of readmission in ICU and/or hospital between SOT patients with GCV-R versus GCV-S CMV-infection.
|
Through study completion, an average of 1 year
|
To compare all cause mortality between SOT patients with GCV-R versus GCV-S CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To compare all-cause mortality during infection episode and follow-up (30, 60, 90 days after the first CMV infection diagnosis) between SOT patients with GCV-R versus GCV-S CMV-infection.
|
Through study completion, an average of 1 year
|
To describe the therapeutic management of GCV-R CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To describe the therapeutic management of GCV-R CMV-infection.
|
Through study completion, an average of 1 year
|
To evaluate differences of CMV-specific T-cell response in patients with GCV-R versus GCV-S CMV-infection.
Zeitfenster: Through study completion, an average of 1 year
|
To evaluate differences of CMV-specific T-cell response in patients with GCV-R versus GCV-S CMV-infection.
CMV-specific T-cell response will be assesed determining the detection of IFN-γ expressed in UI/ml after stimulation of whole blood or peripheral blood mononuclear cells (PBMC) with CMV-specific antigens or overlapping peptides.
|
Through study completion, an average of 1 year
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- ReCySOT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Cytomegalovirus-Infektionen
-
ModernaTX, Inc.Aktiv, nicht rekrutierendCytomegalovirusVereinigtes Königreich, Vereinigte Staaten, Kanada
-
CMV Research FoundationInternational AIDS Vaccine InitiativeAbgeschlossenCytomegalovirusVereinigte Staaten
-
University of Wisconsin, MadisonAbgeschlossenCytomegalovirusVereinigte Staaten
-
University Hospital, LimogesAbgeschlossen
-
University Hospital, LimogesAbgeschlossen
-
Merck Sharp & Dohme LLCAbgeschlossenCytomegalovirus-Infektion | Cytomegalovirus-KrankheitJapan
-
National Taiwan University HospitalUnbekanntCytomegalovirus-EndotheliitisTaiwan
-
Beckman Coulter, Inc.Beendet
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)